Evaluation of a chronic kidney disease risk assessment service in community pharmacies by Gheewala, PA et al.
A
cc
ep
te
d 
A
rti
cl
e
Evaluation of a chronic kidney disease risk assessment service in community pharmacies 
Authors 
Pankti A. Gheewala1; 
Gregory M. Peterson1; 
Syed Tabish R. Zaidi1; 
Matthew D. Jose2; 
Ronald L. Castelino3. 
 
Affiliation(s) and address(es) of the authors 
1Division of Pharmacy, School of Medicine, Faculty of Health, University of Tasmania.  
2School of Medicine, Faculty of Health, University of Tasmania. 
3Sydney Nursing School, The University of Sydney, Australia. 
 
Corresponding author 
Pankti A. Gheewala 
Division of Pharmacy, School of Medicine, Faculty of Health, University of Tasmania 
Private Bag 26, Hobart 7001, Australia  
Email: Pankti.Gheewala@utas.edu.au 
Telephone: +61 0 413 502 243   
Fax: +61 3 6226 7627 
 
Short running title 
Chronic kidney disease risk assessment service in community pharmacies 
 
 
Evaluation of a chronic kidney disease risk assessment service in community pharmacies 
 
Abstract 
Aim 
This article is protected by copyright. All rights reserved.
 
 
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which 
may lead to differences between this version and the Version of Record. Please cite this 
article as doi: 10.1111/nep.13247 
  
A
cc
ep
te
d 
A
rti
cl
e
Targeted ‘opportunistic’ screening might be a sustainable approach for the early detection of people with 
undiagnosed chronic kidney disease (CKD). The aim of this study was to implement and evaluate a CKD risk 
assessment service in the community pharmacy setting. 
Methods 
Twenty-four pharmacies in Tasmania, Australia participated in this study. Targeted people were aged between 50-74 
years, with at least one CKD risk factor. The QKidney® risk calculator was used to estimate the participants’ 5-year 
percentage risk of developing moderate-severe CKD. Participants identified with ≥ 3% risk were referred to their 
general practitioner (GP) and followed-up after 9 months. Laboratory data was collected from a pathology provider. 
The main outcome measures were rates of GP referral uptake and of participants who underwent estimated 
glomerular filtration rate (eGFR) and urine albumin creatinine ratio (ACR) measurement. 
Results  
We analysed data for 389 screened participants, of whom 203 (52.1%) had ≥ 3% 5-year risk of developing moderate-
severe CKD and were referred to their GP. Follow-up was successful for 126 participants and showed low (27%) GP 
referral uptake. Analysis of the pathology data revealed suboptimal kidney testing in participants with ≥ 3% risk, 
with eGFR and ACR tests performed for only 52.7% and 25.1% of these participants, respectively.  
Conclusions 
There is significant scope for improving early detection of CKD via implementation of a community pharmacy-
based CKD risk assessment service. However, a healthcare system that encourages inter-professional collaboration 
between community pharmacists and GPs, and provides a robust referral pathway is needed to optimise the 
effectiveness of this service. 
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Introduction 
A systematic analysis indicated that almost 500 million adults worldwide in 2010 had chronic kidney disease (CKD), 
the burden of which is fuelled by the epidemics of diabetes and hypertension [1]. CKD is a major risk factor for end-
stage kidney disease (ESKD), cardiovascular disease (CVD) and premature death [2]. In Australia, data on the 
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prevalence of CKD is limited and the best available evidence to estimate the CKD burden is drawn from renal 
replacement therapy (RRT) data [3]. At the end of 2014, 959 Australians per million population were undergoing 
RRT [3], and 17% of new patients were referred late to nephrologists for the management of ESKD [4]. A 
retrospective study found that despite the increasing prevalence of CKD in the state of Tasmania, Australia, testing 
for kidney disease (i.e. serum creatinine and albuminuria) in at-risk people was suboptimal [5]. This indicates 
significant evidence-practice gaps and the need to improve early CKD detection. 
Early diagnosis and treatment of CKD has the potential to reduce the risks of CVD and CKD progression by up 
to 50% [2]. Worldwide, many targeted screening programs for CKD have been conducted [6] and an Australian 
screening program ‘Kidney Evaluation for You (KEY)’ found that targeted ‘opportunistic’ screening might prove to 
be a sustainable approach [7]. Community pharmacy-based screening or risk assessment services have shown 
potential in detecting people at high risk of diabetes and CVD [8, 9]. Additionally, pharmacy-based screening and 
health promotion services help to increase public awareness. Pharmacists are highly accessible and in a good position 
to engage people within the community who are not aware of their risks and less likely to access general practice 
care [10]. Hence, pharmacists could play an important role in the early detection, referral and education of 
individuals at risk of CKD.  
Current literature indicates that various risk assessment tools [11-13] can facilitate the early identification of 
people at risk of developing CKD. One such validated tool recommended by Kidney Health Australia (KHA) is the 
QKidney® risk calculator [13-15].  This algorithm, which estimates a person’s risk of developing moderate-severe 
CKD (estimated glomerular filtration rate (eGFR) <45 ml/min/1.73m2) over the next 5 years, was derived using the 
data of over 1.5 million primary care patients from 188 general practices across England and Wales [14]. 
The main aim of this study was to implement and evaluate a CKD risk assessment service, using the QKidney® 
risk calculator, in Tasmanian community pharmacies. Specific objectives were to (i) identify people at risk of 
developing moderate-severe CKD over the next 5 years and refer them to their general practitioner (GP) for further 
evaluation, and (ii) document the outcomes and challenges of implementing a CKD risk assessment service within 
community pharmacy. 
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Methods 
The Tasmanian Health and Medical Human Research Ethics Committee (H0014258) approved this prospective 
cohort study. This study was conducted across 24 Tasmanian community pharmacies between February 2015 and 
March 2016. Geographically, 13 pharmacies were located in the south, 5 were located in the north/north east, and 6 
were located in the north west/west of Tasmania. A letter of invitation explaining the purpose of the study was 
mailed to all (a total of 143) community pharmacies across Tasmania, and those who agreed to participate were 
included . The detailed recruitment process and training of community pharmacists has been described elsewhere 
[16]. Trained community pharmacists (n = 38), final year pharmacy students (n = 2) and a researcher (n = 1) 
conducted this study. Pharmacies received an incentive of $15/participant recruited. Patient participation was 
promoted via posters placed in the pharmacies and by pharmacists, directly approaching eligible individuals arriving 
at the community pharmacy. 
Risk assessment service 
Individuals eligible to participate were aged between 50-74 years, with at least one of the following self-reported risk 
factors: high blood pressure (BP) requiring treatment, diabetes, heart failure (HF), obesity (BMI ≥ 30 kg/m2), current 
smoker, personal history of heart attack, angina, stroke or transient ischaemic attack (TIA), or family history of 
kidney disease. Participants who self-reported having CKD were excluded. The flow diagram for the risk assessment 
protocol is shown in the Supporting Information 1. After written consent was obtained, an assessment data form was 
used to collect participant details, such as demographics (age, gender, ethnicity, address, contact number), GP details, 
clinical information (smoking status, medical history, family history), and medication history (prescription and over 
the counter (OTC) drugs, complementary and alternative medicine (CAM)). Participants were asked to wait for at 
least 5 minutes before their sitting BP was measured using an electronic sphygmomanometer. The first systolic BP 
reading was recorded and classified as per the guidelines for the diagnosis and management of hypertension in adults 
by the National Heart Foundation of Australia [17]. Individual participants’ height and weight were measured; 
subsequently, the calculated BMI was recorded and classified [18]. 
Collected information on age, gender, ethnicity, smoking status, diabetes (type 1 or 2), HF, high BP requiring 
treatment, history of heart attack, angina or TIA, family history of kidney disease, calculated BMI and measured 
systolic BP reading was entered into the online QKidney® risk calculator (version 2014 and 2016) [15]. Participants 
were given a detailed explanation of their risk assessment result, written education material on kidney disease 
(Supporting Information 2), and a copy of their results sheet. As per the KHA recommendations [19], participants 
identified with < 3% likelihood of developing moderate-severe CKD over the next 5 years (low risk) were not 
referred; participants with 3-15% risk (moderate risk) were encouraged to discuss the results with their GP at the next 
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planned visit; and participants with > 15% risk (severe risk) were asked to discuss the results with their GP within the 
next two weeks. We also sent a letter to the GP for each participant identified with ≥ 3% risk; the letter included 
information on the study, and a copy of the individual participant’s assessment data form and results sheet. 
Participant follow-up 
All participants with ≥ 3% risk were followed up by telephone after 9 months. We made three attempts to contact the 
participant by telephone, after which we sent the survey via post. The survey included questions to establish whether 
the participant had: a) discussed their risk assessment results with their GP and b) undergone a ‘Kidney Health 
Check’. According to KHA, a ‘Kidney Health Check’ consists of three tests: blood test for eGFR, urine test for 
albumin-creatinine ratio (ACR), and BP measurement [20]. The survey also included questions to determine if 
participants had made any changes to their lifestyle and disease management strategies as a result of participation in 
this study.  
Pathology data collection 
We obtained participants’ follow-up laboratory data on eGFR and ACR from a major Tasmanian community-based 
pathology laboratory. Participant data on laboratory tests performed within one year after undergoing the risk 
assessment and repeated within 3 months of initial tests for participants with evidence of CKD were included in the 
final analysis. The pathology provider calculated the eGFR by using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formula as per the revised recommendations of the Australasian Creatinine Consensus 
Working Group [21]. Evidence of CKD was defined as an eGFR <60 ml/min/1.73m2 and ACR >3.5 mg/mmol 
(female) or >2.5 mg/mmol (male) [2]. 
Sample size calculation 
Based on the data presented in research that developed and validated the risk assessment calculator [14], and 
extrapolating to an older cohort of individuals with at least one pre-existing risk factor for CKD, we estimated that 50% 
of the sample would have a 5-year risk of moderate-severe CKD of at least 3% (and therefore require referral). Using 
a 5% precision and 99% confidence level (to be 99% sure that the true percentage of the population aged between 50 
and 74 years with at least one CKD risk factor that has a 5-year risk of moderate-severe CKD of at least 3% using the 
risk assessment calculator, is between 45% and 55%) we needed 384 eligible individuals.  
Statistical analysis 
We used the Statistical Package for Social Sciences (SPSS) version 23.0 software to perform statistical analysis. 
Participants with 3-15% moderate-risk were sub-categorised into 3-7.9% moderate-risk 1 and 8-15% moderate-risk 2. 
Descriptive statistics were calculated as mean and standard deviation (SD) for continuous variables, and percentage 
for categorical variables. We used a thematic approach to analyse all answers to the open-ended questions. 
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Results 
Risk assessment service 
The flow diagram for the participant recruitment process is shown in Figure 1. Out of 405 participants initially 
recruited in the study, we excluded 16 participants because either they did not meet the eligibility criteria or we 
received their data after the follow-up timeline had passed. Table 1 shows the demographic and clinical 
characteristics of the 389 participants included in the final analysis. The mean (± SD) age of participants was 63.3 (± 
6.4) years and 50.4% were female. More than half of our sample had two or more risk factors for CKD. Most 
participants (81.2%) had hypertension, 21.9% had type 2 diabetes, 15.9% had a history of heart attack, angina, stroke 
or TIA, and 6.7% had an immediate family history of kidney disease. Of the sample, 14.2% were smokers and 45.2% 
were obese. More than half of the sample (51.7%) were using CAMs, and the most common were vitamin D (21.0%), 
fish oil (15.5%), and magnesium (7.5%); 32.1% were using OTC drugs, and paracetamol (70.7%) was the most 
common of these.  
The online QKidney® risk calculator identified 47.8% participants at low-risk (< 3%), 33.4% at moderate-risk 1 
(3-7.9%), 11.6% at moderate-risk 2 (8-15%), and 7.2% at severe-risk (> 15%) of developing CKD in the next 5 years. 
Almost half (44.6%) of participants had a systolic BP ≥ 140 mmHg; 47.8% and 30.6% of participants with and 
without a reported diagnosis of hypertension, respectively, had a systolic BP ≥ 140mmHg. 
Participant follow-up 
Of 203 participants with ≥ 3% risk, 28 were excluded from the follow-up analysis because 12 had forgotten 
participating in the study, 8 had missing address/contact details and 8 withdrew during follow-up. From the 
remaining 175 participants, follow-up was successful for 126 (72%). Follow-up was not successful for 49 
participants as these did not answer their phone (3 attempts were made) or return the completed survey that was later 
sent via post. The rate of successful follow-up was similar across moderate-risk 1 (71.4%), moderate-risk 2 (74.4%) 
and severe-risk (70.8%) categories. The success rate was highest (75.6%) amongst participants between 60-69 years 
and lowest (60.7%) for the age group 50-59 years. Most (70.6%) participants reported that they became aware of the 
risk assessment service after being approached by a pharmacist for participation.  
Of 126 participants with successful follow-up, 120 (95.2%) had subsequently visited their GP and 34 (27.0%) had 
discussed their results. Of participants (n = 41) who provided reasons for no discussion of the results, 34% mentioned 
that their GP did not initiate discussion on the risk assessment results and, therefore, they did not. Of 34 participants 
with follow-up who had discussed results with the GP, blood test, urine test and BP checks were performed for 26, 
17 and 17 participants, respectively. The percentage of these participants who underwent a complete ‘Kidney Health 
Check’ was 9 (26.5%). During follow-up, 36.4% of participants with hypertension (n = 110) and 48.1% of 
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participants with diabetes (n = 54), agreed that they were prompted to take better care of their hypertension and 
diabetes, respectively, as a result of participation. Of 14 participants with follow-up who were smokers at the time of 
risk assessment, 7 reported reducing the number of cigarettes smoked per day and 1 had stopped smoking.  
Pathology data analysis 
Within one year following risk assessment, eGFR and ACR testing was performed in 52.7% (n = 107) and 25.1% (n 
= 51), respectively, of ≥ 3% risk participants (n = 203). Simultaneous eGFR and ACR test was performed for 19.7% 
(n = 40) participants. Table 2 shows the stratification of participants’ eGFR and ACR data as per their moderate-
severe risk categories. Six participants in the moderate-risk 1 category and one in the moderate-risk 2 category had 
eGFR between 45-59 ml/min/1.73m2; however, repeated eGFR testing was performed for only one participant who 
was under the moderate-risk 1 category. Five, two and one participants in the moderate-risk 1, moderate-risk 2 and 
severe-risk category, respectively, had an ACR between 3.5-35 mg/mmol (female) or 2.5-25 mg/mmol (male). Again, 
repeated ACR testing was performed for a single participant who was in the severe-risk category. 
Withdrawal of community pharmacists 
Fourteen of 38 pharmacists withdrew from the study and the most common reason reported for withdrawal was lack 
of time and staff. Several pharmacists mentioned that, being the only pharmacist on-duty, they were too busy to 
spend 10-15 minutes per participant to conduct the risk assessment effectively.  
 
Discussion  
The community pharmacy-based CKD risk assessment service, with its targeting, identified a high proportion (52.2%) 
of people at ≥ 3% risk of developing moderate-severe CKD within 5 years. However, the follow-up analysis revealed 
that a low proportion (27%) of referred participants had discussed their risk results with their GP. The major reason 
for the low referral uptake was GPs not initiating discussion on the risk assessment results. Also, absence of an 
existing medical complaint might have enhanced participants’ reluctance to initiate discussion [22]. Another 
contributing factor towards the low referral uptake could be the manner in which the results were communicated to 
the GP. All GPs were sent a referral letter; however, it is possible that not all of them had the opportunity to read it 
before the patient visit [23]. On the other hand, GPs might not have agreed with the recommendations of the risk 
assessment and chose not to act or deferred investigation in participants who were already overwhelmed with their 
existing comorbidities. Also, GPs might have over-relied on their patients to initiate discussion on the risk results 
[24]. In any case, the low referral uptake was a major hindrance to the efficacy of the CKD risk assessment service.  
No previous studies have implemented a similar protocol in community pharmacies for CKD; hence, direct 
comparisons could not be made. Upon literature review, we found many pharmacy-based screening studies for 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
diabetes [25, 26], CVD [8] and atrial fibrillation [23], which concluded that screening in community pharmacy is 
effective and feasible. However, this seems to have been overstated because the GP referral uptake reported in the 
majority of these studies [23, 25, 26] was low and ranged from 9.1-42.4%. Only a CVD study [8] reported a high GP 
referral uptake (83%), although the participant loss to follow-up in this study was high (>50%). A recent systematic 
review investigating the effectiveness of pharmacy-based screening services found a significant proportion of 
screened participants do not attend their GPs for follow-up, or GPs often do not act on the referral information [10].  
Additionally, a qualitative study of Australian GPs showed that most did not favour pharmacists’ provision of 
screening services, as they believed screening to be the role of the GP and lacked confidence in the accuracy of 
screening tests and pharmacists’ competence [27]. These findings suggest that any pharmacy-based screening 
services, even with a robust in-pharmacy protocol, are likely to have a low success rate unless there are close 
working relationships between community pharmacists and GPs [28, 29]. More specifically, there is a need to 
develop an innovative referral pathway which can ensure that patients who have undergone screening at community 
pharmacies are subjected to further investigation during their routine visit to the GP [27, 29]. 
A distinctive aspect of our study, compared with other pharmacy-based screening studies, was the availability of 
participant pathology results. The QKidney® algorithm calculates a person’s risk of developing moderate-severe 
CKD over the next 5 years; however, this study identified 15 participants who had evidence of early CKD. For an 
accurate CKD diagnosis, the KHA CARI (Caring for Australasians with renal impairment) guidelines on early CKD 
detection recommend simultaneous and repeated ACR and eGFR measurement; otherwise, an increased incidence of 
both over- and under-diagnosis is likely [30]. Our pathology analysis showed that simultaneous testing was 
performed in only 19.7% of ≥ 3% risk participants and, although more than half of these participants had undergone 
eGFR testing, only about a quarter had their ACR measured. Similarly, in 2007, Jose et al. found that only 50.6% 
and 9.4% at-risk Tasmanians had serum creatinine and albuminuria measured, respectively [5]. Also, our study found 
that repeated ACR or eGFR measurement within three months of initial testing was performed for only 2 (13.3%) out 
of 15 participants with initial evidence of CKD. This suboptimal kidney testing might be attributed to the significant 
gaps, as identified by the AusHEART study, in Australian GPs’ adherence to preventative guidelines and recognition 
of CKD [31]. 
Our pathology analysis revealed that more than half of ≥ 3% risk participants had undergone kidney testing 
(either eGFR or ACR measurement); however, few were aware of it. Similarly, the AusDiab study found relatively 
low recollection of kidney testing even in patients with CKD [32]. This suggests that information sharing by 
providing pharmacists access to patients’ medical records and pathology data would help to prevent unnecessary 
screening, as well as enabling pharmacist review of medication dosing in kidney disease.  
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In terms of the limitations of our study, there are two community-based pathology providers in the state of 
Tasmania. The pathology provider from which the data for this study was collected owns approximately 80% of the 
Tasmanian pathology specimen collection centres and has been operating for approximately 50 years; whereas, the 
other provider has been operating only for the past three years. However, it is possible that relevant pathology data 
for some participants may have been missing. 
Several barriers restricted pharmacists from continuing participation. Future studies should aim to reduce the time 
required to conduct risk assessment. If pharmacy assistants are trained to a) collect participant demographic and 
clinical data, and b) measure height and weight, then this would allow the pharmacists to focus on key aspects, which 
include 1) BP measurement, 2) risk assessment and 3) CKD education. Pharmacists would then need only 5-10 
minutes/participant. Alternatively, the screening would only be performed by pharmacies having more than one 
pharmacist on duty at any time. Lastly, it is possible that kidney testing by the GP was performed as a result of other 
ongoing comorbidities and not as an outcome of risk assessment. 
This study showed considerable scope for improving the early detection of CKD via implementation of a 
community pharmacy-based CKD risk assessment service. In order to improve the referral uptake, we recommend 
that during CKD risk assessment, community pharmacists should put emphasis on the asymptomatic nature of CKD 
and explain to the participant the importance of consulting their GP for a regular ‘Kidney Health Check’. On the 
other hand, a healthcare system that encourages a close working relationship between pharmacists and GPs is needed 
if pharmacy-based risk assessment and screening services are to benefit the public. 
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Figure Legend 
Figure 1 Participant Recruitment process 
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Supporting Information 1 Flow diagram for chronic kidney disease risk assessment protocol 
Supporting Information 2 Educational material on chronic kidney disease 
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Table 1 Participant demographics and clinical characteristics 
Characteristics N % 
Total 389 100 
Mean age (mean ± S.D.., range) 63.3 ± 6.4, 50-74 
Gender   
Female 196 50.4 
Male 193 49.6 
Ethnicity   
White or not stated 383 98.5 
Indian 1 .3 
Other Asian 2 .5 
Other ethnic group 3 .8 
Region (n = 381)   
South 205 52.7 
North/north east 89 22.9 
North west/west 87 22.4 
Smoking status 
Non-smoker  218 56.0 
Ex-smoker 116 29.8 
Light smoker (less than 10 cigarettes/day) 29 7.5 
Moderate smoker (10 to 19 cigarettes/day) 11 2.8 
Heavy smoker (20 or over cigarettes/day) 15 3.9 
Diabetes 
Type 1 5 1.3 
Type 2 85 21.9 
Heart failure 9 2.3 
High blood pressure requiring treatment 316 81.2 
History of a heart attack, angina, stroke or transient ischaemic stroke 62 15.9 
Immediate family* history of kidney disease (*mother, father, brothers or sisters) 26 6.7 
Body mass index (kg/m2) 
Underweight  <18.5 2 .5 
Healthy  18.5-24.9 56 14.4 
Overweight  25-29.9 155 39.8 
Obese  ≥30 176 45.2 
Systolic blood pressure (mmHg) (n = 386) 
Optimal <120 50 12.9 
Normal 120-129 51 13.1 
High normal 130-139 113 29.0 
Grade 1 (mild) hypertension 140-159 128 32.9 
Grade 2 (moderate) hypertension 160-179 38 9.8 
Grade 3 (severe) hypertension ≥180 6 1.5 
Qkidney risk range (%) 
Risk category Percentage risk   
Low <3 186 47.8 
Moderate 1 3-7.9 130 33.4 
Moderate 2 8-15 45 11.6 
Severe >15 28 7.2 
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Table 2 Stratification of participants’ estimated glomerular filtration rate and albumin creatinine ratio data as per 
their moderate-severe risk categories 
  Risk categories 
 Total Moderate-risk 1 
(3-7.9%) 
Moderate-risk 2 
(8-15%) 
Severe-risk 
(> 15%) 
 N % N % N % N % 
Estimated glomerular filtration rate 
(eGFR) (ml/min/1.73m2) (n = 107) 
        
>90 36 33.6 22 61.1 10 27.8 4 11.1 
60-89 64 59.8 40 62.5 14 21.9 10 15.6 
45-59 7 6.5 6 85.7 1 14.3 - - 
30-44 - - - - - - - - 
15-30 - - - - - - - - 
<15 - - - - - - - - 
         
Albumin creatinine ratio  
(ACR) (mg/mmol) (n = 51)  
        
<3.5, female; <2.5, male 43 84.3 26 60.5 9 20.9 8 18.6 
3.5-35, female; 2.5-25, male 8 15.7 5 62.5 2 25 1 12.5 
>35, female; >25, male -  - - - - - - 
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Figure 1 Participant recruitment process 
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